Stallion India Q2 PAT sinks 79% YoY to ₹2.45 Cr as input costs, ESOP charge crush margins
PAT -78.5% YoY · revenue +28.9% · margins compressing · miss vs street
₹136.03 Cr
+28.9% YoY
₹2.45 Cr
-78.5% YoY
1.76%
-9pp YoY
₹0.21
Stallion India Fluorochemicals' standalone Q2 FY27 print is a clear miss on profitability even as revenue held up: revenue from operations grew 28.9% YoY (and 12.0% QoQ) to ₹136.03 Cr, ahead of our pre-result on-plan range of ₹120-128 Cr, but PAT collapsed 78.5% YoY and 86.8% QoQ to just ₹2.45 Cr, with EPS falling to ₹0.21 from ₹1.60 in Q1 FY27 and ₹1.42 a year ago. There is no formal sell-side coverage on this stock (0 analysts per public trackers), so the only external yardstick is our own preview, which had flagged ~14-15% PAT margin and ~₹20-23 Cr EBITDA as the on-plan bar; actual PAT margin came in at 1.8% and reported EBITDA (PBT less other income, plus finance costs and depreciation) at just ₹2.98 Cr — a clear miss on profitability despite the revenue beat.
Q2 FY-2027 vs prior quarters
Two factors drove the collapse. First, a one-off: the company booked a ₹9.51 Cr non-cash ESOP expense (15,86,505 options granted at a Black-Scholes fair value of ₹128.69/option) entirely within Q2, per Note 5 of the filing — this alone explains most of the ~5x jump in employee costs. Adjusting for it, PAT would have been roughly ₹11.96 Cr, a YoY growth of just +4.8% (essentially flat) rather than the reported -78.5%. Second, and more concerning, raw material costs consumed 88.2% of revenue this quarter versus 62.5% in Q1 FY27 and 75.1% in the year-ago quarter — even stripping out the ESOP charge, OPM works out to roughly 9.2%, still down sharply from 18.15% in Q1 FY27 and 14.75% a year ago. Management's prior guidance (Q1 FY27 concall) had called for EBITDA margins to improve 3-4 percentage points over the medium term; this quarter moved in the opposite direction by several hundred basis points even on an adjusted basis, a direct miss against that outlook. Revenue growth of 28.9% YoY is roughly tracking, if a touch below, the guided 30-35% three-year revenue CAGR.
The stock went into the print at ₹188, down 10.6% over the past month of trading.
For context: revenue is at a 6-quarter high.
30-35% revenue CAGR over 3 years maintained; EBITDA margins to improve 3-4% over medium term. R32 plant contributes ₹125 Cr in Q4 FY27 (down from prior ₹250 Cr guidance). Helium facility (1,200 MT) targeting 20% utilization in FY28 (~240 MT); peak revenue >₹1,100 Cr in FY28 at ~15% PAT margin.
— This quarter: missed
No management press release or concall commentary for this specific quarter is available in our records, so there is no company framing to cross-check against the numbers beyond the filing itself. The quarter's other disclosed developments — commercial start-up of the Semiconductor Gas facility at Khalapur (Sept 21, 2026) and conclusion of a GST inspection with tax paid (Oct 15, 2026, quantum not separately disclosed in this filing) — sit alongside the print but aren't yet visible as margin drivers; the semiconductor ramp is still early. Half-year PAT (₹21.02 Cr) is down 3.5% YoY despite 19.2% YoY revenue growth to ₹257.48 Cr, showing the margin pressure is not confined to a single quarter's optics.
W1
Whether the ₹9.51 Cr ESOP charge was a one-time Q2 catch-up or recurs in Q3 FY27's employee cost line
W2
Raw material cost ratio (88.2% of revenue this quarter) needs to normalize toward the 62-75% range seen in prior quarters for the guided 3-4pp EBITDA margin improvement to stay credible
W3
Semiconductor Gas facility (commercial ops from Sep 21, 2026) and Helium facility ramp contribution to Q3 FY27 revenue/margin, against management's FY28 target of >₹1,100 Cr revenue at ~15% PAT margin
Standalone only, no consolidated statement filed; employee benefit expense jumped ~5x QoQ (₹238.71L to ₹1,197.56L) almost entirely due to a ₹950.92L non-cash ESOP charge (Note 5) booked in Q2; raw material cost also spiked to 88.2% of revenue from 62-75% in comparison quarters.
Can Stallion sustain Q1's margin burst as helium facility ramps?
Strong Q1 earnings beat on volume growth and operational leverage set a high bar. Q2 will test whether the newly commissioned Semiconductor Gas facility can maintain momentum into the seasonally softer half, and whether margins hold near record highs.
The bar: Q1 set a high one
Stallion India Fluorochemicals posted a blowout Q1 FY27: standalone revenue climbed 9.9% YoY and 10.4% QoQ to ₹121.45 Cr, while net profit surged 79% YoY to ₹18.57 Cr, with EBITDA margins expanding sharply. The company signalled strong operating leverage from its core specialty chemicals (refrigerants, fluorine-based intermediates) alongside early contributions from recently commissioned capacity (the 10,000 MTPA R-32 facility came online by August). For Q2, investors will watch whether this momentum persists and whether the newly commissioned Semiconductor & Specialty Gas facility (Khalapur, commenced September 2026) begins to add material revenue.
~₹120–128 Cr
On-plan growth trajectory: +7–11% YoY (mid-range ₹124 Cr), +1–5% QoQ. Semiconductor Gas facility began ops in Sep; contribution likely marginal in Q2 as startup ramp takes time.
~14–15%
Q1 delivered 15.2% (₹18.57 Cr PAT on ₹121.45 Cr revenue) — a 150bps expansion. Normalization to 14–15% is on-plan; margins may face minor seasonal/input headwinds in Q2.
~₹20–23 Cr
Estimate based on 16–18% EBITDA margin (typical post-expansion), supporting prior guidance on operating leverage.
What on-plan vs weak looks like
On-plan: Revenue ₹122–126 Cr (7–10% YoY growth), PAT ₹17–19 Cr (14–15% margin). This marks solid sequential momentum with the foundry base holding and helium facility adding low single-digit ₹ Cr revenue in its first full operational quarter. EBITDA margin stable ~16–17%. The company maintains its FY28 guidance (>₹1,100 Cr revenue, 15% PAT margin) without commentary shifts. Weak: Revenue misses ₹120 Cr (growth <7% YoY) or PAT drops below ₹16 Cr (margin <13%). This could signal helium facility delays, softness in refrigerant/fluoro-intermediate demand, or margin pressure from raw material costs. Input inflation (HF, chlorine, energy) is a watch point in specialty chemicals, and any supply-chain disruption to the new facility would be flagged.
On track for FY27–28 guidance?
The company guided for FY28 revenue >₹1,100 Cr with a 15% PAT margin. At the current run-rate — Q1 at ~₹490 Cr annualized revenue, and assuming Q2–Q4 average ~₹120 Cr/quarter — FY27 revenue could land ~₹460–480 Cr (roughly in line with a prior-year base for a 10–12% ramp year). The new Semiconductor Gas facility should materially pull FY28 into the >₹1,100 Cr zone if ramp proceeds on schedule (full capacity contribution expected in H2 FY27–H1 FY28). Q2 will be the first test of this facility in a full operating quarter. Any slippage in ramp or demand would jeopardise the FY28 target.
Since last quarter: the filings scan
Semiconductor Gas facility live (Sep 19): Commercial operations commenced at the Khalapur debulking and blending plant — a strategic move into high-margin specialty gases (high-purity helium, neon, argon for semiconductor/electronics). The facility is designed for 1,200 MT annual capacity; contribution in Q2 will be early-stage ramp. GST inspection closed (Oct 15): Maharashtra State GST authorities completed their inspection and search at the registered office. The company cooperated and settled tax liability. Routine compliance closure — no material regulatory overhang flagged. Trading window closed (Sep 28): Compliance-driven closure ahead of result announcement. No insider-trading red flags reported in the block-deal data (Junomoneta bulk trades in July were buy/sell pairs at ₹205 — routine liquidity flow). Promoter stake steady: Shareholding: FII 0.83%, DII 1.53%, Promoter 47.80% (Q1 FY27). No major stock pledge or dilution signals in recent filings.
1 · Semiconductor Gas revenue & margin
How much did the helium/specialty gas facility contribute in its first full quarter? Look for commentary on utilization rates, pricing, and when management expects full-capacity contribution. This will calibrate FY28 growth.
2 · Core refrigerant/fluoro demand trajectory
Stripped of the helium facility, is the base business (R-32, HFC-410A, fluorine intermediates) holding growth? Demand signals here indicate whether the 7–11% YoY growth is sustainable or facing seasonal/cyclical headwinds.
3 · Input costs & margin guidance
Q1 saw 150bps margin expansion — unprecedented. Is this a durable uplift (pricing power, mix shift, scale) or a one-time beat that normalizes? Input inflation (HF, energy) is a risk in specialty chemicals. Listen for commentary on cost trajectory and revised FY27–28 margin guidance.
Stallion India Fluorochemicals faces a credibility test in Q2: can it sustain Q1's margin fireworks and demonstrate that the new Semiconductor Gas facility is a real growth driver, not a one-time capacity sink? Revenue is likely on-plan at ₹120–128 Cr (7–11% YoY growth), but the margin story — whether it holds near Q1's 15.2% or normalizes lower — will determine whether the market retains confidence in the FY28 >₹1,100 Cr target.
The stock at ₹196.88 is down 45% from all-time highs but up 98% from 52-week lows, reflecting the volatility of specialty-chemical micro-caps. Catalyst clusters (facility ramp, margin trajectory, any M&A or capacity expansion announcements) are key to re-rating higher. Watch for early-ramp commentary and demand signals from the semiconductor gas side on Nov 13.